Fig. 6: Multivalent VLPs and pseudotyped VSV incorporating NiV F/G, HeV F/G, and EBOV GP elicited neutralizing antibodies in hamsters. | npj Vaccines

Fig. 6: Multivalent VLPs and pseudotyped VSV incorporating NiV F/G, HeV F/G, and EBOV GP elicited neutralizing antibodies in hamsters.

From: Multivalent viral particles elicit safe and efficient immunoprotection against Nipah Hendra and Ebola viruses

Fig. 6

A. Negative control hamsters were vaccinated with bald VLPs. Serum for the hamsters’ terminal bleed was used to neutralize monovalent NiV F/G, HeV F/G, EBOV GP, and the multivalent pseudotyped VSV particles and entry of the virus into the cells was analyzed by Renilla Luciferase assay. The mean neutralization read out for the monovalent and multivalent pseudotyped VSV was calculated and graph plotted using Graphpad software. B Monovalent and multivalent pseudotyped VSV were neutralized with different dilutions of sera from hamsters vaccinated with multivalent VLP vaccine. Virus neutralization was done in a similar manner as the negative controls. The average neuralization read outs were calculated and graph derived using Prism Graphpad software. C Hamsters were vaccinated with the multivalent pseudotyped VSV. Sample processing was done as for the negative controls. The mean neutralization read out was calculated and graph derived using Prism graphpad software. D, E Normalized graphs for sera from hamsters vaccinated with the multivalent VLPs and pseudotyped VSV. F Forty microliters of VLP and pseudotyped VSV preparations were analyzed by Western blotting to compare incorporation of glycoproteins following observation that pseudotyped VSV was eliciting a relatively stronger immune response compared to VLPs.

Back to article page